News
Current report No. 23/2023 – Correction of the Periodical Report
Legal basis: Article 56 subs. 1 point 2 of the Act on Public Offering – current and periodical information The Management Board of Celon Pharma S.A. (“Company”) hereby informs that in the “Half-Year Condensed Financial Statements for the 6-month period ended June 30, 2023” published by the Company on 20 September 2023, there was, forRead more »
Current report No. 22/2023 – Signing of an agreement for the implementation and co-funding of Celon Pharma S.A.’s project on clinical development of the innovative CPL110 inhibitor in FGFR-dependent solid tumors
Date prepared: 07/25/2023 Abbreviated name of the issuer: CELON PHARMA S.A. Subject: Signing of an agreement for the implementation and co-funding of Celon Pharma S.A.’s project on clinical development of the innovative CPL110 inhibitor in FGFR-dependent solid tumors Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – inside information. Content ofRead more »
Current report No. 21/2023 – Receipt of a notification regarding a change in the total number of votes in the Company
Date prepared: 07/25/2023 Abbreviated name of the issuer: CELON PHARMA S.A. Subject: Receipt of a notification regarding a change in the total number of votes in the Company Legal basis: Article 70 point 1 of the Act on Public Offering – acquisition or disposal of a significant block of shares Content of the report: TheRead more »
Current report No. 20/2023 – Change in the composition of the Management Board of Celon Pharma S.A.
Date prepared: 07/04/2023Abbreviated name of the issuer: CELON PHARMA S.A.Subject: Change in the composition of the Management Board of Celon Pharma S.A.Legal basis: Article 56 subs. 1 point 2 of the Act on Public Offering – current and periodical information Content of the report:The Management Board of Celon Pharma S.A. the “Company” hereby informs that onRead more »
Current report No. 19/2023 – Appointment of existing members of the Company’s Supervisory Board for another term
Date prepared: 06/23/2023 Abbreviated name of the issuer: CELON PHARMA S.A. Subject: Appointment of existing members of the Company’s Supervisory Board for another term Legal basis: Article 56 subs. 1 point 2 of the Act on Public Offering – current and periodical information Content of the report: The Management Board of Celon Pharma S.A. (“Company”)Read more »
Current report No. 17/2023 K – Resolutions adopted by the Ordinary General Meeting of Celon Pharma S.A. on June 22, 2023 – correction
Date prepared: June 27, 2023 Abbreviated name of the issuer: CELON PHARMA S.A. Subject: Resolutions adopted by the Ordinary General Meeting of Celon Pharma S.A. on June 22, 2023 – correction Legal basis Article 56 subs. 1 point 2 of the Act on Public Offering – current and periodic information Content of the report: InRead more »
Current report No. 18/2023 – List of shareholders holding at least 5% of the votes at the Ordinary General Meeting of Celon Pharma S.A. held on June 22, 2023
Date prepared: June 22, 2023 Abbreviated name of the issuer: CELON PHARMA S.A. Subject: List of shareholders holding at least 5% of the votes at the Ordinary General Meeting of Celon Pharma S.A. held on June 22, 2022 Legal basis subs. 70 point 3 of the Act on Public Offering – General Shareholder’s Meeting, theRead more »
Current report No. 17/2023 – Resolutions adopted by the Ordinary General Meeting of Celon Pharma S.A. on June 22, 2023
Date prepared: July 22, 2023 Abbreviated name of the issuer: CELON PHARMA S.A. Subject: Resolutions adopted by the Ordinary General Meeting of Celon Pharma S.A. on June 22, 2023. Legal basis Article 56 subs. 1 point 2 of the Act on Public Offering – current and periodic information Content of the report: The Management BoardRead more »
Current report No. 16/2023 – Resolution of the Ordinary General Meeting of the Company on coverage of loss and payment of the dividend for the financial year 2022
Date prepared: July 22, 2023 Abbreviated name of the issuer: CELON PHARMA S.A. Subject: Resolution of the Ordinary General Meeting of the Company on coverage of loss and payment of the dividend for the financial year 2022 Legal basis Article 56 subs. 1 point 2 of the Act on Public Offering – current and periodicRead more »
Current report No. 15/2023 – Statement of the Central Securities Depository of Poland (KDPW) on assimilation of 21,500 C-series shares with the Company’s shares currently traded in the stock exchange
Date prepared: June 15, 2022 Abbreviated name of the issuer: CELON PHARMA S.A. Subject: Statement of the Central Securities Depository of Poland (KDPW) on assimilation of 21,500 C-series shares with the Company’s shares currently traded in the stock exchange Legal basis: Article 56 subs. 1 point 2 of the Act on Public Offering – currentRead more »